The rate-limiting step of cholesterol biosynthetic pathway is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme reductase (HGMR), whose inhibitors, the statins, widely used in clinical practice to treat hypercholesterolemia, often cause myopathy, and rarely rhabdomyolysis. All studies to date are limited to the definition of statin-induced myotoxicity omitting to investigate whether and how HMGR inhibition influences muscle functions. To this end, 3-mo-old male rats (Rattus norvegicus) were treated for 3 wk with a daily intraperitoneal injection of simvastatin (1.5 mg/kg/d), and biochemical, morphological, mechanical, and functional analysis were performed on extensor digitorum longus (EDL) muscle. Our results show that EDL muscles from simvastatin-treated rats exhibited reduced HMGR activity; a 15% shift from the fastest myosin heavy-chain (MHC) isoform IIb to the slower IIa/x; and reduced power output and unloaded shortening velocity, by 41 and 23%, respectively, without any change in isometric force and endurance. Moreover, simvastatin-treated rats showed a decrease of maximum speed reached and the latency to fall off the rotaroad (ϳ؊30%). These results indicate that the molecular mechanism of the impaired muscle function following statin treatment could be related to the plasticity of fast MHC isoform expression.-Trapani, L., Melli, L., Segatto, M., Trezza, V., Campolongo, P., Jozwiak, A., Swiezewska, E., Pucillo, L.P., Moreno, S., Fanelli, F., Linari, M., Pallottini, V. Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions. FASEB J. 25, 4037-4047 (2011). www.fasebj.org
is crucial for myoblast differentiation to occur (9) ; indeed, HMGR inhibition or down-regulation lead to both the reduction of muscle differentiation markers [myogenin and fetal myosin heavy chain (f-MHC)] and of myoblast fusion into multinucleated syncitia (9) .
Although these combined findings bring out the importance of HMGR activity in skeletal muscle physiology, all the studies so far are limited to the definition of statin-induced myotoxicity, omitting to investigate whether and how the inhibition of HMGR activity influences muscle functions. Moreover, epidemiological studies show that some patients treated with statins complain of muscle pain without any increase in plasma content of muscle damage markers, such as serum CK (4) , which suggests that HMGR inhibition could impair muscle function without exerting any muscle toxicity.
Here we studied in vivo the role of HMGR inhibition by simvastatin on skeletal muscle physiology through biochemical, morphological, mechanical, and functional approaches.
MATERIALS AND METHODS

Reagents
All chemicals were obtained from commercial sources and of the highest quality available. Sources not specified were obtained from Sigma-Aldrich (Milan, Italy).
Animals
Wistar Rattus norvegicus, 3-mo-old male (Harlan Nossan, S. Pietro al Natisone, Italy), were housed under controlled temperature (20Ϯ1°C), humidity (55Ϯ10%), and illumination (lights on for 12 h daily, from 7 AM to 7 PM). Food and water were provided ad libitum. The experiments were performed according to the ethical guidelines for the conduct of animal research (Ministero della Salute, Official Italian Regulation No. 116/92, Communication to Ministero della Salute no. 391/121). Rats were divided into 2 groups of 28 animals each. The first group was treated daily with intraperitoneal injection of 1.5 mg/kg simvastatin in vehicle [dimethyl sulfoxide (DMSO), 1 ml/kg] for 3 wk, a dose comparable to the highest one used in therapies against human hypercholesterolemia. Control animals received daily an equal volume of vehicle. At the end of the treatment, rats were anesthetized with ether in a fume cupboard, and plasma was obtained from blood collected into EDTA (1 mg/ml blood). Extensor digitorum longus (EDL) and gastrocnemius muscles of 7 animals/group were dissected and immediately frozen in liquid nitrogen for subsequent biochemical assays. Eight animals from each group were used for mechanical analyses; in particular, after dissection, EDL muscles were mounted in an experimental trough to analyze the contractile properties. For immunolocalization studies, EDL muscles from both sides of 3 animals/group were isolated and fixed by immersion in phosphate-buffered saline (PBS; pH 7.4) containing 4% freshly depolymerized paraformaldehyde, overnight at 4°C. For rotarod motor coordination test and open-field locomotor activity, 10 animals/group were used.
Biochemical analysis
Plasma cholesterol analysis
Plasma cholesterol content of rats was assessed through the colorimetric CHOD-POD kit (Assel, Rome, Italy) according to manufacturer's instructions. Briefly, by the catalysis of cholesterol esterase and cholesterol oxidase, cholesterol ester was catalyzed to yield H 2 O 2 , which oxidates 4-aminoantipyrine with phenol to form a colored dye of quinoneimine. The absorbancy increase is directly proportional to the concentration of cholesterol.
Tryglyceride and creatin kinase assays
Plasma triglyceride levels and creatin kinase activity were measured by standardized commercial methods on a fully automated system (Modular; Roche, Basel, Switzerland). Triglycerides are hydrolyzed to glycerol by lipoprotein lipase and oxidized to dihydroxyacetone phosphate and hydrogen peroxide, which reacts with Trinder reagent to form a red dye. The color intensity is directly proportional to triglyceride concentration. This method is linear between 4 and 1000 mg/dl. Activity of creatin kinase measurement is in accordance with the method recommended by the International Federation of Clinical Chemistry at 37°C.
HMGR activity
The assay was carried out with the radioisotopic method, following the production of
14 C]-HMGCoA; specific activity 57.0 mCi/mmol; GE Healthcare, Little Chalfont, UK). Microsomes were prepared as described previously (10) from gastrocnemius. Microsomes were incubated in presence of cofactors (20 mM glucose-6 phosphate, 20 mM NADP ϩ sodium salt, 1 IU glucose-6 phosphate dehydrogenase, and 5 mM dithiothreitol). The assay, in a final volume of 200 l, was started by the addition of 10 l (0.088 Ci/11.7 nmol) of 3-[
14 C]-HMG CoA. The [ 14 C]-MVA produced was isolated by chromatography on AG1-X8 ion-exchange resin (Bio-Rad Laboratories, Milan, Italy), and the radioactivity was counted by a liquid scintillation analyzer (Tri-Carb 2100 TR; Canberra Packard, Schwadorf, Austria [b] ). An internal standard (3-[ 3 H]-MVA, specific activity 24.0 mCi/mmol; GE Healthcare) was added to calculate the recovery.
Membrane and lysate preparation
Total membrane and total lysate were obtained as follows: 100 mg skeletal muscle tissue was homogenized in 0.01 M TrisHCl, 0.001 M CaCl 2 , 0.15 M NaCl, and 0.001 M PMSF (pH 7.5). An aliquot of homogenate was collected and used for lysate preparation. The remaining homogenate was centrifuged for 20 min at 10,000 g. The supernatant was centrifuged at 100,000 g for 45 min, and the pellet was resuspended and centrifuged again at 100,000 g for 45 min. The pellet was solubilized in 0.125 M Tris-HCl (pH 6.8) containing 10% SDS and protease inhibitor cocktail (sample buffer) and transferred into microtubes. The aliquot of homogenate was solubilized by sonication in sample buffer and centrifuged for 5 min at 15,600 g, and the supernatant was transferred into microtubes. Protein concentration was determined by the method of Lowry et al. (11) . All samples were boiled for 3 min before loading for Western blotting.
Protein analysis
Protein profiles were analyzed by Western blotting. Western blot analysis of LDLr and RhoA were performed on total gastrocnemius and EDL plasma membranes, respectively, while the analysis of MHC isoforms, poly(ADP-ribose) polymerase-1 (PARP-1), AMPK␣, and Akt were performed on total EDL lysates. Protein (20 g) from solubilized membranes was resolved by 12% (for RhoA), 10% (for P-Akt, total Akt, P-AMPK␣, and total AMPK␣), and 7% (for LDLr, MHC isoforms, and PARP-1) SDS-PAGE at 100 V for 60 min. SDS-PAGE for MHC isoforms was performed at 140 V for 6 h at 4°C. The proteins were subsequently transferred electrophoretically onto nitrocellulose for 90 min at 100 V. The nitrocellulose membrane was blocked at room temperature with 5% fat-free milk in Tris-buffered saline (138 mM NaCl, 27 mM KCl, 25 mM Tris-HCl, and 0.05% Tween-20, pH 6. 
Lipid extraction
EDL muscle (ϳ100 mg) was homogenized in NaCl (150 mM; 1:9, w/v); 6 nmol coenzyme Q6 (CoQ6), 600 l water, 4 ml methanol, and 4 ml chloroform were added to homogenate. CoQ6 was added as internal standard to calculate the recovery. The samples were incubated for 30 min at 37°C. Then, 800 l NaCl 150mM and 2 ml chloroform were added, and 2 phases were obtained. The lower phase was evaporated with a stream of nitrogen. Samples were dissolved in 0.5 ml chloroform and then divided into halves. The samples used to measure CoQ9 amount were dissolved in 50 l isopropanol:ethanol (1:1, v/v); the samples employed to estimate cholesterol and dolichol levels were hydrolyzed in 0.5 ml 15% KOH in ethanol:water (95:5, v/v) for 60 min at 95°C. Then the organic phase was extracted with 0.5 ml of water and 1 ml of hexane. The upper phase was collected and evaporated with a stream of nitrogen, then dissolved in 50 l isopropanol:ethanol (1:1, v/v).
HPLC-UV analysis of polyisoprenoids
Lipids were analyzed according to previously described protocol (12) with modifications. Briefly, two parallel runs, one for CoQ9 and another for cholesterol, were performed on a 4.6-ϫ 75-mm Zorbax XDB-C18 (3.5 m) reversed-phase column (Agilent, Santa Clara, CA, USA) using a Waters dual-pump apparatus, a Waters gradient programmer, and a Waters photodiode array detector (spectrum range: 210 -400 nm; Waters Corp., Milford, MA, USA). For elution, a combination of convex gradients (Waters No. 5, from 0 to 75% B for the initial 20 min and linear, from 75 to 100% B during the following 10 min) was used; in the last 5 min, reequilibration back to 0% B was performed, where solvent A was methanol: water (9:1, v/v), and solvent B was methanol:propan-2-ol/ hexane (2:1:1, v/v/v). The solvent flow rate was 1.5 ml/min. HPLC solvents were obtained from POCh (Gliwice, Poland 
Morphological analysis
Fixed EDL muscles were dehydrated in graded ethanol, transferred to Bioclear (BioOptica, Milan, Italy) and then to a 1:1 mixture of Bioclear and paraffin, and finally embedded in paraffin. Transverse, 7-m-thick sections were cut by a microtome and collected on Vectabond precoated slides (Vector, Burlingame, CA, USA). Sections were deparaffinized, rehydrated, and submitted to antigen retrieval, using antigen unmasking solution (Vector). After cooling, slides were transferred to PBS containing 3% hydrogen peroxide, for 5 min, in the dark, then to PBS with 0.2% Triton X-100 and 3% bovine serum albumin (BSA), for 1 h at room temperature. Sections were incubated overnight at 4°C with either of the following mouse polyclonal antibodies, diluted in PBS containing 0.1% Triton X-100 and 1.5% BSA: fast MHC MY-32 1:1000, slow MHC NOQ7.5.4D 1:5000 (Sigma). In control sections, the primary antibody was omitted. Slides were then incubated for 1 h at room temperature with biotinylated goat anti-rabbit IgG (Vector), diluted 1:200 in PBS containing 1% normal goat serum (Vector). Immunocomplexes were revealed by means of an avidin biotin system (Vectastain Elite ABC kit, Vector), using 3,3Ј-diamino-benzidine (DAB Substrate kit for peroxidase; Vector), as the chromogen. Sections were counterstained with hematoxylin, then dehydrated and mounted with Eukitt (Kindler GmbH & Co., Freiburg, Germany). Slides were observed under an Olympus BX 51 microscope (Olympus, Tokyo, Japan) equipped with a Leica DFC 420 camera (Leica Microsystems, Wetzlar, Germany); electronic images were captured by a Leica Application Suite system, and composed in an Adobe Photoshop CS2 format (Adobe Systems, San Jose, CA, USA).
Mechanical analysis
EDL muscle was dissected by using scissors and forceps under a stereomicroscope (Stemi SV11; Carl Zeiss MicroImaging, Oberkochen, Germany) and mounted horizontally, between the lever of a motor/force transducer system (305C, Aurora Scientific Inc., Aurora, ON, Canada) and a lever carried by a micromanipulator, in a trough, containing physiological solution (Krebs-Henseleit solution, composition, in mM: 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.0 MgSO 4 , 25 NaHCO 3 , 1.2 KH 2 PO 4 , and 1.1 glucose) gassed with carbogen (95% O 2 and 5% CO 2 , pH7.4). The muscle was straightened just above its slack length by means of the micromanipulator. The trough was sealed with a Perspex cover and mounted vertically on the stage with the motor/force transducer system on top. The solution was continuously saturated with carbogen during the experiment. Room temperature was in the range 20 -22°C.
Trains of stimuli of alternate polarity to elicit fused tetani (frequency 70 -80 Hz) were delivered by means of two platinum wire electrodes running parallel to the muscle, 1 cm apart. The intensity of the stimuli was increased until the isometric plateau force reached a maximum constant value T 0 (indicating that all the cells in the muscle were activated). The muscle length was finely adjusted further by means of the micromanipulator to obtain the maximum isometric force, corresponding to the plateau of the force-length relation. To compare isometric force among muscles, the isometric plateau force was normalized by the wet weight of the muscle, measured at the end of each experiment with an electrobalance (CP124S; Sartorius, Goettingen, Germany). The forcevelocity relation was determined by measuring the velocity of steady shortening V after a drop in force from the isometric value T 0 to a preset value TϽT 0 . The force-velocity points were fitted to the Hill hyperbolic equation (Eq. 1):
where a, b, and V 0 (the unloaded shortening velocity) are the regression parameters.
To investigate the effects of simvastatin on muscle endurance, a fatiguing protocol was used. EDL muscle was given a 400-ms fused tetanus every 3 s over a period of 150 s. The muscle was then allowed to recover for a period of 40 min, during which force recovery was monitored with a tetanus every 5 min. Force, length change, and stimulus were recorded with a multifunction I/O board (PCI-6110E; National Instruments, Austin, TX, USA) at 0.5-ms sampling rate. A program written in LabVIEW (National Instruments) was used for signal recording and analysis.
Functional analysis
Rotarod motor coordination test
To assess any effect of simvastatin on motor coordination and balance, rats were tested in an automated accelerating rotarod apparatus (Biological Research Apparatus; Ugo Basile, Varese, Italy; ref. 13 ). The apparatus consisted of 7-cmdiameter plastic drums machined with grooves to improve grip, that could be set on accelerating speed (4, 10, 12, 15, 19, 22, 26, 29 34 and 40 rpm, 30 s at each speed).
Before testing, the rats were trained for 2 d, applying the following schedule (14) : the first day, the rats were trained for 3 min with an unlimited number of trials on the rotarod, followed by 4 trials of maximum 60 s with a 30 s intertrial interval; the second day, the rats were placed on the rotarod at accelerating speed for a maximum of 300 s. Testing was performed after 21 d of treatment with simvastatin; each rat was individually placed on the rotarod at accelerating speed for a maximum of 300 s, and the latency to fall off the rotarod and the maximum speed reached within this time period were recorded. Immediately after each session, the apparatus was thoroughly cleaned with cotton pads wetted with 70% ethanol;water solution and dried. Rats were allowed to habituate to the experimental room for 60 min before both training and testing. Training and testing were performed between 10:00 AM and 1:00 PM.
Open-field locomotor activity
The day after rotarod testing, the rats were tested for horizontal locomotor activity. The animals were transferred from the holding room to the experimental room, where they were allowed to habituate for 60 min. Testing was conducted under dim light between 10:00 AM and 1:00 PM. The test started by placing each animal in the center of an open-field arena (80ϫ80 cm) made of gray Plexiglas. Behavior was videorecorded for 10 min using a digital video camera for subsequent analysis. All scores were assigned by the same observer, who was unaware of animal treatment. Immediately after each session, the apparatus was thoroughly cleaned with cotton pads wetted with 70% ethanol:water solution and dried. The following behavioral parameters were scored: number of crossings (crossing with both forepaws the lines in which the floor of the arena was subdivided on the monitor), time spent near the walls (periphery), time spent in the central part of the arena, and frequency and duration of rearing (standing with the body inclined vertically, forequarters raised), wall-rearing (standing on the hind-limbs and touching the walls of the apparatus with the forelimbs), and grooming (rubbing the body with paws or mouth and rubbing the head with paws).
Statistical analysis
Data are expressed as means Ϯ sd. The difference of parameters was statistically tested for significance with unpaired Student's t test. Values of P Ͻ 0.05 were considered to indicate a significant difference. Statistical analysis was performed using GraphPad Instat3 (GraphPad, Inc., La Jolla, CA, USA) and SigmaPlot (Systat Software Inc., San Jose, CA, USA) for Windows.
RESULTS
Simvastatin efficacy and tolerance
Simvastatin efficacy in lowering plasma LDL-cholesterol (15) and triglycerides (16) by hepatic LDLr up-regulation (17) was verified by checking rat plasma cholesterol and triglyceride content ( Table 1) . As expected, both the metabolic parameters decreased significantly with the following treatment, by 30% and 53%, respectively. Nevertheless, simvastatin treatment did not modify animal weight, even though the weight of treated animals was slightly lower than that of rats receiving vehicle (Fig. 1A) . Moreover, simvastatin treatment lowered HMGR activity in the gastrocnemius muscle by 20% (Fig. 1B) . Evidence for drug efficacy on skeletal muscle was also given by the increased levels of LDLr protein in the gastrocnemius muscle of treated rats (Fig. 1C) , in good agreement with the rise of LDLr mRNA observed previously (18) .
Once simvastatin efficacy on skeletal muscle was ascertained, our attention focused on the effects exerted by HMGR inhibition on EDL muscle, which consists mainly of fast and glycolitic fibers, given that the glycolitic fibers appear to be the most susceptible to statin side effects (19) . Thus, the levels of HMGR end products involved in skeletal muscle contraction, such as CoQ9 (4), cholesterol (3), and a prelynated protein (RhoA) (5, 20), were assessed. As shown in Table 2 , no significant differences were detected in EDL muscles of simvastatin-treated rats either in cholesterol or in CoQ9 content. In addition, as shown in Fig. 2A , the translocation of RhoA on EDL plasma membrane and its consequent activation (21) did not differ in simvastatintreated animals when compared to controls.
Effects of simvastatin treatment on muscular damage
To ascertain whether the pharmacological treatment could have caused possible muscle damage, as described previously (2, 8) , plasma CKs (22) , and muscle cleaved PARP-1 protein levels, markers for muscle fiber necrosis and apoptosis, respectively, were checked (Fig.  2B, C) . Both CK and PARP-1 protein levels were not increased in simvastatin treated rats with respect to the control showing the absence of muscle fiber necrosis and/or apoptosis.
MHC isoform determination
Previous data demonstrated that HMGR inhibition by mevinolin (3 M) can modulate fetal MHC expression in L6 myoblasts (9) . This finding prompted us to assess whether a putative modification of MHC isoform expression could occur in EDL muscle after simvastatin treatment. Morphological observation of sections from simvastatin-treated EDL muscles indicated unaltered cytoarchitecture, compared to controls. The immunohistochemical localization of fast and slow MHC isoforms on EDL muscles from simvastatin-treated and control rats showed similar, though not identical, distribution of positive fibers in either conditions (Fig. 3) .
Muscle cells immunoreactive to anti-fast MHC isoform
represented the large majority of fibers in sections from both treated and untreated muscles (Fig. 3A, B) . However, the occurrence of negative fibers, most probably corresponding to slow MHC isoform-expressing cells, appeared to be increased after treatment. Accordingly, simvastatin seemed to produce an increased frequency of slow MHC immunoreactive fibers, as shown in Fig.  3C , D, but the data are not statistically significant. Moreover, an enhanced immunodensity of the positive cells was detected after the pharmacological treatment, suggesting that the expression of slow MHC isoform could be higher under this condition. Immunohistochemical analysis suggests that a change in fiber structure could occur. To better ascertain putative differences in MHC isoform expression, Western blot analysis was performed. As observed in Fig. 4A , no differences were detected in the slow MHC isoform expression. The apparent discrepancy between the data obtained by immunohistochemistry and those obtained by Western blot can be explained if the low percentage of EDL fibers expressing the slow MHC isoform is considered. Thus, Western blot analysis is not sensitive enough to detect the difference highlighted through morphological observation. Electrophoresis separation shows a shift of the fast MHC isoforms, from the fastest MHC IIb to the slower MHC IIa/x (Fig. 4B ) in the simvastatin-treated rats with respect to control. In the control group, EDL muscle contained ϳ85% of MHC IIb isoform, with a small (15%) amount of MHC IIa/x isoforms, while EDL muscle of simvastatin-treated rats contained ϳ70% of MHC IIb isoform, and 30% of MHC IIa/x isoforms.
Statin treatment can interfere with the intracellular pathways responsible for MHC isoform switch; thus, the activity of Akt and of AMPK, whose phosphorylation states were demonstrated to be modified by statins (23, 24) , was analyzed. In particular, Akt and AMPK are negative and positive regulators, respectively, of peroxisome proliferator-activated receptor-␥ coactivator 1-␣ (PGC-1␣), which plays a central role in muscle plasticity (25) . Figure 5 shows that no changes in the phosphorylation levels of these two kinases are observable after simvastatin treatment. 
Effect of simvastatin treatment on muscle function
To understand whether the observed shift from the fastest MHC IIb isoform to the slower MHC IIa/x isoforms could affect the mechanical properties of EDL muscle, the effects of simvastatin treatment on the contractile properties of fast skeletal muscle were evaluated. In particular, the maximum steady force elicited by the isometric tetanus T 0 , twitch-to-tetanus ratio t/T 0 , time to attain half of the isometric tetanic plateau force t 1/2 , and force-velocity relation ( Table 3 and Fig. 6 ) were recorded. T 0 was normalized by the different mass of muscles by mean of the procedure described in Materials and Methods. Simvastatin treatment, with respect to control, reduced T 0 and t/T 0 by 23 and 22%, respectively (but the difference is not statistically significant; Table 3 ); significantly increased t 1/2 by 25% (Table 3) ; and reduced the shortening velocity at any load below T 0 (Fig. 6C and Table 3 ). Consequently, the power, calculated as the product T ⅐ V, was significantly reduced in simvastatintreated rats (Fig. 6D) . At the load for the maximum power, ϳ0.3 T 0 , the power (W max ) was 41% lower in simvastatin-treated than in control rats ( Table 3 ). The unloaded shortening velocity V 0 , estimated as parameter of the Hill hyperbolic equation (Eq. 1), was 23% lower in simvastatin-treated than in control rats (Table 3) . To investigate whether simvastatin treatment affects not only power but also endurance, EDL muscles were subjected to a fatigue protocol (see Materials and Methods). Results showed no difference in the time course of isometric force reduction to get 40% of the prefatigue value (Fig. 7) , indicating that endurance performance is not affected by simvastatin treatment. Also, the time course of force recovery from fatigue, over 40 min from the end of the fatigue protocol, which allows isometric force to recover ϳ30% of force decay in control, showed no effect of simvastatin treatment (ascending part of the curves in Fig. 7 ).
Rotarod motor coordination and open-field locomotor activity tests
To assess further whether the effects of simvastatin on skeletal muscle could result in functional impairments, we tested the effect of this treatment regimen on motor coordination and locomotor activity in rats. Treatment with simvastatin impaired performance in the rotarod test. Indeed, simvastatin-treated rats showed reduced latency to fall off the rotarod and reduced maximum speed reached during test compared to vehicle-treated animals (Fig. 8) . Simvastatin-treated rats did not differ from vehicle-treated rats for any parameter measured in the open-field test (number of crossings, Fig. 9A ; Fig. 8C ; data not shown for frequency and duration of wall-rearing, rearing, and grooming).
DISCUSSION
In the current study, we investigated the role of HMGR inhibition by simvastatin on skeletal muscle physiology. This lipophilic HMGR inhibitor was chosen because the lipophilic statins are generally taken up much more widely into a broad range of tissues and cells by diffusion compared with hydrophilic statins (26) . Chronic treatment with simvastatin (1.5 mg/kg) inhibits HMGR activity in skeletal muscle to a similar extent as in the liver, where the effect of statins is well documented (19) ; induces a shift of MHC isoforms toward a slower phenotype; reduces the power output and the unloaded shortening velocity of EDL muscle without a significant reduction in isometric force and resistance to fatigue; and induces functional impairment, i.e., reduction in the latency to fall off the rotarod.
Because power involves not just force production but also the speed at which the force is produced, deficits in muscle power can be related to impairment in movement Four muscles contributed to each value. Statistical analysis was done by unpaired t test. Isometric contraction parameters: L 0 , muscle length at the plateau of the force-length relation; w, muscle wet weight; CSA, cross-sectional area of muscle, calculated using the relation CSA ϭ w/(L 0 ‫)␦ء‪k‬ء‬ (cm and locomotion (27, 28) . Biochemical analysis shows that simvastatin treatment, by means of the shift toward a slower MHC isoform phenotype, reduces EDL muscle functions without exerting any muscle damage, in agreement with the lack of evidence for reduction in isometric force.
The drug efficacy on skeletal muscle tissue was ascertained by determining HMGR activity and LDLr protein levels. In agreement with previous studies in hepatocytes, simvastatin inhibits HMGR activity and increases the expression of LDLr (19) . The putative myotoxic effects of the drug, whose underlying mechanisms are still debated, were excluded by the analysis of muscle damage markers. It is known that statin administration can induce muscle fiber necrosis, with release of cellular constituents such as CK into the bloodstream (2), and a caspase-dependent apoptotic cascade leading to the PARP-1 cleavage (29) . Any significant increase of plasma CK and cleaved PARP-1 protein levels in simvastatin-treated rats was found, indicating that, in agreement with the lack of evidence for reduction in isometric force, the reduced muscle function is not related to muscle fiber loss due to apoptosis or necrosis. The absence of muscle damage could be explained by the lower dose of simvastatin used in our study, 1.5 mg/kg (comparable to the highest dose used to treat hypercholesterolemia in the clinical practice), with respect to the doses used in previous studies where muscle damages were described (30) . In fact, the maximum simvastatin dose administered in clinical practice is 80 mg/d, corresponding, on average, to 1.14 mg/kg/d; since the metabolism rate of rats is higher than that of humans, the dose administered to the animals was slightly increased. We also excluded that the impairment of EDL muscle function was due to modified levels of HMGR end products directly involved in muscle contraction; neither cholesterol nor CoQ9 changed significantly in treated animals. However, this result cannot rule out a modulation of HMGR main end products by simvastatin, since only 50% of the body CoQ9 is derived from endogenous synthesis through the MVA pathway, and the remaining 50% is thought to be obtained through fat ingestion (4) and carried mainly by LDL in the circulation (12) . Thus, like cholesterol, putative CoQ9 depletion due to enzyme inhibition by simvastatin could have been restored within the cells and, in turn, within the tissues by an enhanced LDLr-mediated uptake, as suggested by the increased LDLr protein expression. Furthermore, the levels of RhoA were evaluated both because the post-translational modification with a prenyl group (an HMGR product) is necessary for its membrane association and consequent activation, and because RhoA can activate Rho-kinase, responsible for MLC phosphorylation and, in turn, involved in the regulation of muscle contraction. Nevertheless, RhoA activation state did not change in either animal group.
Morphological but overall biochemical analysis show a change of sarcomeric proteins belonging to the contractile machinery of the muscle toward a slower phenotype, especially in the MHC composition of the fibers within the muscle, which leads to the reduced muscle function (31, 32) . Specifically, simvastatin treatment induces a shift from the fastest MHC IIb isoform to the slower MHC IIa/x isoforms. The amount of reduction of V 0 (23%), W max (41%), and t 1/2 (25%), as well as the lack of significant change in T 0 , are in qualitatively good agreement with the changes of these parameters described in muscles and in fully Ca 2ϩ -activated skinned fibers from fast skeletal muscles of mammalians containing different MHC isoforms (31) (32) (33) (34) (35) . In particular, fast fibers from rats containing pure MHC IIa isoform have V 0 ϳ30% lower than those containing MHC IIx isoform, and the latter have V 0 ϳ20% lower than fibers containing MHC IIb isoform, while the maximum power in fibers containing MHC IIa/x isoforms is 30 -60% lower than in fibers containing MHC IIb isoform (33) . Moreover, the endurance of EDL muscle, determined by a fatigue protocol, is not affected by simvastatin.
The simvastatin-induced impairment of muscle performance was also supported by an in vivo functional test. These changes resulted in reduced maximum speed reached and reduced latency to fall off the accelerating rotarod in the absence of general impair- ments in basal locomotor activity, as measured in the open-field test. Thus, simvastatin-treated rats showed normal coordination and were still able to run on the rotarod at low speeds but, compared to vehicle-treated animals, could not run the rod at high speeds.
Our results indicate that the simvastatin-induced impairment of muscle function is not related either to changes in Akt and AMPK phosphorylation or to changes in HMGR end products directly involved in muscle contraction, suggesting that a putative modification of other MVA pathway downstream compounds, such as prenylated proteins (i.e., Cdc42, Ras, Rac) not evaluated in this work could be at the root of the observed phenomena (Fig. 10) .
Further investigations must define the molecular mechanisms responsible for the fast MHC isoform plasticity. This work establishes that a shift in the fast MHC isoforms is involved in muscle contraction impairment following statin treatment. The observed fast MHC isoform shift could be responsible for the reduced muscle activity, at least in fast muscle, and functional impairment described in statin-treated pa- Figure 9 . Effects of simvastatin in the open-field test. Simvastatin-treated rats did not differ from vehicle-treated rats in the number of crossings (tϭ0.67, dfϭ17, n.s.; A) and in the time spent both in periphery (tϭ0.51, dfϭ17, n.s.; B) and in center (tϭϪ0.53, dfϭ17, n.s.; C). Moreover, simvastatin-and vehicle-treated rats did not differ in frequency and duration of wall-rearing, rearing, and grooming (data not shown); n ϭ 10/group. (38) , which, in turn, causes an increase of AMPK activity (23) ; and can suppress Akt phosphorylation. Both the activation of AMPK and the suppression of Akt phosphorylation positively modulate PGC-1␣, which drives a coordinated conversion to fibers having characteristics of oxidative type I, IIa, and IIx fibers (25) . The lack of any modification in both Akt and AMPK phosphorylation and the absence of changes in HMGR main end products (cholesterol, CoQ9, RhoA) found here, exclude their involvement in MHC shift to slower phenotype in our experimental model. The shift could be ascribable to other prenylated proteins involved in intracellular signal transduction pathway (dotted line in the scheme).
tients (4, 36) . This finding suggests that alternative pharmacological approaches should be considered in the management of hypercholesterolemia.
